Company: Theravance Biopharma, Inc.
Headquarters: George Town, Grand Cayman, Cayman Islands (operational HQ: South San Francisco, CA, USA)
Founded: 2014 (spin-off from Theravance, Inc.)
Ticker: TBPH (NASDAQ)
Employees: ~300
Market Cap: ~$1.5B (2024)
Theravance Biopharma is a biopharmaceutical company with a strategic focus on gastrointestinal (GI) disorders, showcasing the intersection of enteric nervous system science and Parkinson's disease autonomic dysfunction. The company's marquee product, Resolor (prucalopride) for chronic constipation in women, addresses one of the most prevalent and disabling non-motor symptoms of PD — constipation affecting 60-80% of patients[1].
Theravance Biopharma was established as a separate entity in March 2014 when its parent company Theravance, Inc. restructured into two companies: Innoviva (retaining the respiratory franchise with GSK royalties) and Theravance Biopharma (retaining the GI program and other pipeline candidates)[2].
Mechanism of Action:
Prucalopride is a selective, high-affinity serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist:
Pharmacological Differentiation from First-Generation Prokinetics:
| Feature | Prucalopride | Metoclopramide | Domperidone |
|---|---|---|---|
| Selectivity | 5-HT4 selective | D2 + 5-HT4 | D2 only |
| CNS effects | Minimal (BBB penetration low) | Moderate (psychiatric side effects) | Moderate (prolactin elevation) |
| Cardiac risk | Low | Moderate (QT prolongation) | Moderate (QT prolongation) |
| PD interaction | Safe (no dopamine antagonism) | Contraindicated (blocks dopamine) | Caution needed |
Prucalopride's 5-HT4 selectivity and PD safety profile make it uniquely positioned for the PD constipation market.
Prucalopride addresses PD-associated constipation through mechanisms ideally suited for PD patients:
PD patients on levodopa commonly experience constipation-related "delayed-on" or "no-on" motor fluctuations because slowed gastric emptying delays levodopa absorption. Prucalopride can address this by accelerating GI motility and stabilizing the absorption window[1:1].
| Attribute | Details |
|---|---|
| Brand Name | Resolor (EU/Canada) / Motegrity (US) |
| Generic Name | Prucalopride |
| Formulation | Oral tablets (1 mg, 2 mg) |
| Indication | Chronic constipation (women in EU; all adults in US) |
| Dosing | 2 mg once daily |
| Approvals | EU (2009), Canada (2011), US FDA (2018) |
| Manufacturer | Shire (EU/CA) to Takeda; Motegrity US by Salix/Takeda |
Efficacy in Chronic Constipation:
Safety Profile:
PD-Specific Observations:
Observational studies in PD patients with constipation have shown:
| Program | Indication | Mechanism | Status |
|---|---|---|---|
| Amprepotimod (TD-1473) | Inflammatory bowel disease | JAK/Tyk2 inhibitor (local GI) | Phase 2 |
| Izencitinib (TD-5202) | Crohn's disease | JAK1 selective (gut-selective) | Phase 1 |
Fasano A, et al. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015. ↩︎ ↩︎